Results 81 to 90 of about 16,492 (195)

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

Journal of Lipid Research, 2010
Proprotein convertase, subtilisin/kexin type 9 (PCSK9), a key regulator of plasma LDL-cholesterol (LDL-c) and cardiovascular risk, is produced in liver and secreted into plasma where it binds hepatic LDL receptors (LDLR), leading to their degradation ...
Jeffrey D. Browning, Jay D. Horton
doaj   +1 more source

The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 8, August 2026.
Inflammation in cardiovascular disease is a dynamic and context‐dependent network rather than a secondary response to injury. Mitochondrial danger signaling links metabolic stress to immune activation through TLR priming, NLRP3 inflammasome amplification, cGAS–STING signaling, and immunometabolic gating, providing a basis for more precise therapeutic ...
Jiaxiang Rong, Zhen Wang, Xiaoxiao Lin, Ziwen Lei, Qianqian Huang, Hang Liu, Fei Luan, Junbo Zou, Yajun Shi   +8 more
wiley   +1 more source

LDL receptor-independent mechanisms of proprotein convertase subtilisin/kexin type 9 in cardiovascular pathophysiology

Frontiers in Cardiovascular Medicine
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a pivotal regulator of lipid metabolism and a validated therapeutic target in cardiovascular disease (CVD). While its canonical role in mediating low-density lipoprotein receptor (LDLR) degradation
Hang Su, Xunan Guo, Qiang Li, Xiaohang Yuan, Xiaolong Wu, Zihan Zhao, Yi Kan, Yifan Yang, Zhaolin Fu, Zhenrui Qi, Guangyuan Song   +10 more
doaj   +1 more source

Damping amyloid‐associated conformational fluctuations in a protein by an engineered diselenide bridge

Protein Science, Volume 35, Issue 8, August 2026.
Abstract Polypeptide cross‐β assembly, characteristic of diverse proteotoxic diseases, defines a general thermodynamic ground state and limits the shelf lives of peptide‐ and protein therapeutics. A model is provided by insulin. Although the hormone contains a predominance of α‐helix, its fibrils exhibit cross‐β reorganization.
Yanwu Yang, Balamurugan Dhayalan, Andreas Ehnbom, Orit Weil‐Ktorza, Norman Metanis, Michael A. Weiss   +5 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease

Frontiers in Aging Neuroscience, 2019
Alzheimer’s disease (AD) has been associated with dysregulation of brain cholesterol homeostasis. Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond the known role in the regulation of plasma low-density lipoprotein cholesterol, was first ...
Maria Pia Adorni, Massimiliano Ruscica, Nicola Ferri, Franco Bernini, Francesca Zimetti   +4 more
doaj   +1 more source

Whole‐transcriptome sequencing analyses identified exosomal circular RNAs in the plasma of pancreatic cancer patients as novel blood‐based biomarkers of disease

VIEW, Volume 7, Issue 4, August 2026.
Pancreatic cancer (PaCa) has a poor prognosis, with low resection rates and high relapse rates, highlighting the urgent need for novel diagnostic biomarkers. Here, we performed whole‐transcriptome sequencing of plasma‐derived exosomes from PaCa patients and identified several differentially expressed circular RNAs (circRNAs).
Xiaomeng He, Yang Di, Lixiang Sun, Zhirong Wu, Mengting Luo, Xin Zhang, Huaqin Sun, Wanli Xu, Wenchuan Wu, Boheng Zhang, Jin Wang   +10 more
wiley   +1 more source

A short review of proprotein convertase subtilisin/kexin type 9 inhibitors

Reviews in Cardiovascular Medicine, 2019
Cardiovascular disease is the leading cause of morbidity and mortality globally, as estimated by the World Health Organization, where in 2016, 15.2 million deaths were attributed to ischemic heart disease and stroke. It is therefore essential to try to reduce the incidence of Cardiovascular disease by controlling modifiable risk factors. One such major
openaire   +2 more sources

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7403-7415, August 2026.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Elevated serum galectin‐3 levels predict the incidence of type 2 diabetes mellitus in a Japanese general population: A 10‐year follow‐up study

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1400-1408, August 2026.
Elevated serum galectin‐3 levels are associated with the incidence of T2DM independent of insulin resistance, particularly among non‐obese individuals. There may be a diabetogenic mechanism that is not mediated by obesity or insulin resistance. ABSTRACT Aims/Introduction Although several studies have reported elevated serum galectin‐3 levels in type 2 ...
Harumi Takubo‐Yoshimura, Mika Enomoto, Ako Fukami, Nagisa Morikawa, Yume Nohara‐Shitama, Hiromi Sato, Mayo Shimoyama‐Yamamoto, Hisashi Adachi, Yoshihiro Fukumoto   +8 more
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.

Clinical and experimental rheumatology, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation, and which has been linked to cardiovascular risk. The purpose of the present study was to examine whether PCSK9 serum levels are disrupted in patients with systemic sclerosis (SS ...
Ferraz Amaro, Iván, Delgado Frías, Esmeralda, Hernández Hernández, Vanessa, Sánchez Pérez, Hiurma, Armas Rillo, Laura de, García Dopico, José Antonio, Díaz González, Federico   +6 more
openaire   +2 more sources